SCHEMBL2302015

SCHEMBL2302015

COC(=O)c1ccc(N)c(F)c1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 7/20 0.56
SOS1 Q07889 1/20 0.48
ALDH1A1 P00352 5/20 0.46
GAA P10253 5/20 0.46
KDM4E B2RXH2 5/20 0.46
HSD17B10 Q99714 3/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
GLA P06280 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
ABL1 P00519 1/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31439012 0.87 CFTR (0.56) CFTRSOS1ALDH1A1GAAKDM4E
SCHEMBL13575544 0.81 ALDH1A1 (0.53) CFTRALDH1A1GAAKDM4EHSD17B10
SCHEMBL2295241 0.81 SOS1 (0.58) CFTRSOS1ALDH1A1GAAKDM4E
SCHEMBL23581891 0.80 KDM4E (0.51) CFTRALDH1A1GAAKDM4EHSD17B10
SCHEMBL28937989 0.79 CFTR (0.55) CFTRSOS1ALDH1A1GAAKDM4E
SCHEMBL28564514 0.79 CFTR (0.61) CFTRSOS1ALDH1A1GAAKDM4E
SCHEMBL4387642 0.78 GAA (0.50) CFTRALDH1A1GAAKDM4EHSD17B10
SCHEMBL13715480 0.77 ABL1 (0.56) CFTRALDH1A1GAAKDM4EHSD17B10
SCHEMBL23537740 0.77 ABL1 (0.56) CFTRALDH1A1GAAKDM4EHSD17B10
SCHEMBL2324567 0.77 SOS1 (0.47) CFTRSOS1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3793994-B1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2023-08-23 EP disclosed
EP-3793994-B1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2023-08-23 EP disclosed
EP-3793994-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2021-03-24 EP disclosed
US-10899753-B2 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2021-01-26 US disclosed
WO-2012067664-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-05-24 WO disclosed
WO-2011103063-A1 THERAPEUTIC COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10899753-B2 Inhibiting agents for Bruton's tyrosine kinase ABL1, BTK, LYN CFTR 3044/4885SOS1 741/4885ALDH1A1 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.